Cannabis Research: Medical Promise, Teen Brain Development, and Regulatory Barriers

The podcast brings together two cannabis researchers to discuss medical cannabis, teen brain development, and policy barriers that shape research and patient care.

• Cannabis market complexity and product variability across routes and formulations
• 11,000-teen longitudinal study links cannabis use to slower cognitive gains
• Potential medical applications for pain and seizures with dose considerations
• Policy changes could ease study and improve clinical data capture

Overview and context

The podcast examines how states legalization of recreational cannabis has coincided with a surge in use and a proliferation of products, creating many questions for researchers. It cites the rise from an estimated 25 million users to about 70 million in 2023 and frames cannabis research as a field needing guardrails, standardization, and careful policy navigation. The discussion features two scientists active at the forefront of cannabis research: Dr. Ryan Van Drae, an experimental psychologist at Johns Hopkins Cannabis Science Laboratory, and Dr. Natasha Wade, a neuropsychologist focused on adolescent brain development. Their conversation covers medical potential, routes of administration, product formulations, and the societal context that shapes scientific inquiry.

Market complexity and scientific guardrails

The researchers note that unlike alcohol, cannabis encompasses multiple compounds such as THC, CBD, CBG and others, and has a wide variety of delivery methods including oral dosing, inhalation with devices, topicals, and even suppositories. This leads to a multitude of variables—dose, route, formulation, and user history—that affect outcomes. The discussion emphasizes that few regulatory guardrails exist on cannabis product claims, which forces scientists to repeatedly reassess questions about safety, efficacy, and abuse potential in a rapidly evolving market. The era is described as one of constant reevaluation, with ongoing debates about the best ways to study a plant with dozens of active constituents acting on multiple receptors in the brain.

Teens and cognitive development

Dr. Wade summarizes findings from a longitudinal study following about 11,000 youths across the United States over roughly a decade. By ages 16–17, more than 2,000 had started using cannabis. The key takeaway is that teens who began using cannabis did not show the same gains on cognitive tests over time as their non-user peers, even after controlling for alcohol use, nicotine, prenatal exposure, early mental health concerns, family factors, and sociodemographic variables. While the data show an association between adolescent cannabis use and reduced cognitive trajectory, the researchers caution against claiming causality. They describe cognitive gains as improvements on repeated testing over adolescence, and note that cannabis users often plateau or show less improvement than non-users on these measures.

Medical uses and dose considerations

The endocannabinoid system is discussed as a homeostatic regulator of various physiological processes. Cannabis and cannabinoids show promise for pain management, mitigating chemotherapy adverse effects, and reducing seizures in certain epilepsy forms. The scientists discuss dosing variability, noting reports from an Israeli company using a metered dose inhaler achieving clinical effects with doses as low as about half a milligram of THC—low enough to avoid noticeable cognitive impairment in some patients. They emphasize that the needed dose depends on the desired effect, age, sex, and prior cannabis experience. The conversation also touches on the idea that cannabis is a blunt instrument pharmacologically and that future directions aim to isolate constituent-specific effects to develop targeted therapeutics with fewer side effects.

Policy implications and access to research

The panel discusses how policy changes, such as rescheduling certain medical cannabis products, could facilitate research by allowing scientists to purchase and study products available in dispensaries. They highlight two research streams: human laboratory studies to compare product differences and health-system studies to observe real-world cannabis use. Federally illegal status currently complicates the collection of accurate health data, as patients may not disclose cannabis use to doctors or have access to regulated products, limiting evidence on health outcomes. The discussion also considers how dispensaries, bud tenders, and pharmacists vary in their ability to provide evidence-based guidance, and how medical oversight is often lacking in adult-use markets. Data capture in electronic health records and research cohorts is presented as essential to understanding health effects at a population level.

Practical guidance and ethics

Advice to consumers centers on education about product types, administration routes, and the difference between achieving therapeutic effects with or without intoxication. The speakers advocate “start low, go slow” while acknowledging that illness-specific therapies may not require a high level of impairment. They also stress caution for adolescents, emphasizing the ongoing development of the brain and the absence of clear evidence of benefit for healthy teens. The speakers urge patients to discuss cannabis use with clinicians and to recognize the variability of products across markets. They reflect on the excitement and responsibility in cannabis research, underscoring the policy relevance of the science and the goal of maximizing benefits while minimizing harms.

Closing reflections

Both scientists express a shared commitment to advancing cannabis research in ways that can meaningfully influence public health and policy. They point to a future in which cannabinoid-based therapies are more precisely matched to patient needs, with better data driving regulatory decisions at federal, state, and local levels. The discussion closes on an optimistic note about the potential therapeutic benefits of cannabis while acknowledging the substantial risks and unknowns, and the ongoing, necessary work ahead.